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Abstract
Background The PatientsLikeMe Organ Transplants
online community allows patients to share detailed health
information for research.
Objectives The objectives of our study were to describe
and contrast data collected through an online community
with the broader organ transplant population.
Methods Quantitative data were examined with respect to
basic demographic characteristics and quantitative data
including treatment, symptoms, side effects, and the
PatientsLikeMe Quality of Life (PLMQOL) scale. Quali-
tative data including forum discussion posts and treatment
evaluations were examined to support future development
of standardized questions that could be added to the plat-
form. Online data were compared with US national registry
data from the United Network for Organ Sharing (UNOS).
Results Within 30 days of account creation, 1,924 single-
organ transplant patients provided spontaneous, patient-
reported data in the form of 915 reported symptoms, 938
treatment episodes, and 1,215 PLMQOL assessments. Rela-
tive to patients in the UNOS registry, online participants were
more likely to be female, younger, and white. Lung transplant
patients had worse quality-of-life scores than other organs.
Average organ transplant quality-of-life scores were most
similar to those of HIV patients, faring better than patients
with epilepsy, fibromyalgia, mood disorders, Parkinson’s
disease, multiple sclerosis, or ALS. Site users generated 2,169
posts to 346 unique topic threads in the transplants forum.
Conclusions Organ transplant patients are willing to
report detailed health data through online communities
across key domains—symptoms, treatment effects, and
generic quality of life—that constitute the essential core of
patient-reported outcomes. Patient-reported outcomes
captured online have the potential to accelerate learning
about patient experiences but suffer methodological chal-
lenges that must be overcome to maximize their utility.
Key Points for Decision Makers
• The Internet is no longer just where patients go to read
leaflets or chat in forums, they are using the same tools
used in clinical research studies to learn more about
managing their disease and contribute to research.
• The number of patients online today is relatively small
but is growing rapidly.
• Immediate access to patients who have received an
organ transplant provides a different type of data to
public health statistics or claims data—with an emphasis
on the lived experience of disease.
• Encouraging patients to support one another to over-
come their disease challenges could ultimately improve
health outcomes.
• Online research platforms have strengths and weak-
nesses that suggest they should be deployed primarily
for patients with serious long-term conditions, particu-
larly those affecting females under the age of 60 years,
in order to maximize engagement.
• Online platforms suffer from rapid attrition, which
suggests key data should be captured at first visit.
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Organ transplantation is a condition requiring life-long
maintenance, and may dramatically impact a patient’s
quality of life [1]. The selection of candidates for transplant
is contentious, so powerful data-collection mechanisms
exist to monitor important long-term outcomes such as
organ failure or death and improve the allocation of scarce
organs through the United Network for Organ Sharing
(UNOS). However, even after a successful transplant,
patients face medical and personal challenges such as
monitoring their health, adhering to medication, and coping
with emotions related to their transplant such as guilt, fear,
and responsibility, data that are not gathered easily—
technology may provide one solution.
Patients with chronic health conditions have been using
email and online message boards for more than 30 years to
have conversations in which they learn about their condi-
tions and share information about or advocate for better
care [2]. In more recent times, social networks such as
Facebook have reduced the barriers to communicating
online and drawing attention to health issues. Facebook
itself recently added the ability for users to report their
organ donor status, for example, and permits advocacy
groups to raise awareness about the need for more donors.
Today, transplant recipients can use online message
boards, such as the TransplantBuddies Forum (http://www.
transplantbuddies.org) and its companion social network
site TransplantFriends (http://www.transplantfriends.com).
Social networks have already shown some early promise in
supplementing traditional research methods. Mohammad
and colleagues recently reported on long-term outcomes in
pediatric liver transplant recipients treated in Chicago (IL,
USA) between 1988 and 1992, where they used Facebook
to contact young adults who were otherwise lost to follow-
up as their contact details changed [3]. However, sites that
permit only social sharing (e.g., text stories, photographs,
and hyperlinks) stand in contrast to newer online commu-
nities that integrate data sharing and analysis of quantita-
tive information about the patients’ treatment and health
(e.g., diagnoses, treatments, dosages, symptoms, and out-
comes), such as 23andMe (http://www.23andme.com) and
PatientsLikeMe (http://www.patientslikeme.com).
Originally launched for patients with amyotrophic lat-
eral sclerosis (ALS) in 2006, today any patient may join
PatientsLikeMe to share information, learn from others,
and exchange support [4]. Patients self-report benefits such
as improved health literacy, better communication with
healthcare professionals, and development of a peer sup-
port network [5, 6], and efforts are underway to validate
these objectively. The platform has also been proven useful
in developing patient-reported outcomes (PROs), informed
by the patient’s own language and experience of disease
[7–9]. In 2010, PatientsLikeMe collaborated with Novartis
Pharmaceuticals to develop and launch an online commu-
nity for organ transplant patients. In this paper we describe
key characteristics of the community, assess their quality of
life relative to other patients using PatientsLikeMe, and
consider the benefits and limitations of such a tool.
2 Methods
2.1 Participants
Patients reporting a single-organ transplant, limited to heart,
lung, liver, kidney or pancreas, and who created accounts
between 1 March 2010 and 31 December 2010 were eli-
gible for study inclusion. The beginning date in this
observation period is the date the site was opened for
patients with organ transplants and the end date was chosen
to allow comparison with other complete-year statistics.
Patients can report multiple-organ transplants but the large
number of possible permutations lead to groups too small to
analyze here. Users are under no requirement to enter any
data and they may choose to report as much data as they like
according to any schedule, but can be prompted with
optional reminders. Each potential data point may be
reported both prospectively and retrospectively (e.g.,
symptoms, treatment starts and stops, treatment evaluations,
lab test results, quality of life). To create a common baseline
reference for comparisons among groups of patients defined
by organ type, we examined the ‘most recent’ report offered
by a patient within 30 days of the date they created their
PatientsLikeMe account. Thus, here we describe the status
of organ transplant patients at approximately the time they
created a PatientsLikeMe account during the period
1 March 2010 through 31 December 2010.
Select demographic characteristics of US-based
PatientsLikeMe members reporting a transplant in 2010
were compared with data collected through UNOS, pub-
licly available through the Organ Procurement and Trans-
plantation Network (OPTN). To contextualize transplant
patients’ quality of life we also compared the baseline
quality of life reported by transplant patients during
March–December 2010 with new members of Patients-
LikeMe communities that existed during the same time
period [epilepsy, fibromyalgia and myalgic encephalomy-
elitis (ME), HIV, mood disorders, multiple sclerosis, Par-
kinson’s disease, and ALS] [6]. To address the question of
attrition in online studies we report usage statistics.
2.2 Quantitative Analysis
Basic demographics (birth date, age, gender, race/ethnicity,
highest educational attainment, and insurance status) and
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transplant history information (organ type, date of trans-
plant, transplant center, co-morbid conditions, and donor
characteristics) were solicited from each PatientsLikeMe
user. Users also may choose to share more detailed infor-
mation about the following:
• Lab values (including blood pressure, serum creatinine,
and glomerular filtration rate, calculated using the
Modification of Diet in Renal Disease (MDRD-4)
equation [10])
• Symptoms
• Treatments (pharmacological and non-
pharmacological)
• Quality of life per the PLMQOL
Pre-defined symptom surveys consisting of five primary
symptoms (insomnia, depressed mood, pain, fatigue, and
anxious mood) were available to all users, supplemented by
organ-specific symptoms that were included on the basis of
a literature review and clinician input. In addition to the
pre-defined symptom lists, patients have the ability to add
and monitor symptoms of importance to them—these
added symptoms are coded against the Medical Dictionary
for Regulatory Activities (MedDRA) and (if necessary)
corrected for spelling errors or merged to duplicate terms
by a health data integrity team at PatientsLikeMe. Patients
can also input treatment information including start date,
purpose, dosage, and end date, and have the option to add
treatment evaluations by answering brief questions about
perceived treatment efficacy, adherence, burden, and cost,
with an open text field for comments and advice to other
patients.
Quality of life is measured using the PLMQOL version
2, a 24-item generic quality-of-life questionnaire developed
for use on the site in order to avoid the costs and usage
restrictions of a licensed instrument. The PLMQOL shares
a similar conceptual framework to the widely used the
RAND Corporation SF-36 [11] and contains 24 items
mapped to three domains: physical (11 items), mental (8
items), and social (5 items). Psychometric validation
demonstrated acceptable Cronbach’s alpha for each sub-
scale (a[ 0.8) and strong correlation between the relevant
subdomains of the PLMQOL and the RAND SF-36
[physical function (r = 0.847, p \ 0.001), emotional well-
being/mental (r = 0.842, p \ 0.001), social function
(r = 0.808, p \ 0.001)] [12]. For this report, we calculated
domain summary scores such that physical scores range
from 0 to 44, mental scores from 0 to 32, and social scores
from 0 to 20. Higher scores indicate better quality of life.
For eligible patients, data in the above fields were
examined and analyzed using SPSS Statistics (IBM,
Armonk, NY, USA). Group differences were examined
using Pearson’s Chi-square test when comparing distribu-
tions and F-ratios when comparing mean differences.
2.3 Qualitative Analysis
Patients are able to interact with other PatientsLikeMe
users by posting to threaded message forums, by leaving
comments or questions on other user’s profiles, or through
the system’s private messaging system. Qualitative data
are also collected through an open text field in treatment
evaluations. We systematically reviewed free-text col-
lected from the PatientsLikeMe Organ Transplants Forum
and spontaneously reported treatment evaluations to
identify additional issues important to patients using
PatientsLikeMe. For the purposes of this research, forum
posts and treatment evaluations completed between
1 March 2010 and 31 December 2010 were harvested and
analyzed using IBM SPSS Text Analytics for Surveys
version 4.0.
IBM SPSS Text Analytics uses linguistic-based text
analysis algorithms to identify concepts (words or word
groups) and types (semantic groupings of concepts) which
are used by the analyst to build categories of responses for
analysis and interpretation. Initial extraction of concepts
and types produces a list and a frequency report of how
many of the posts contain each concept or type. We
reviewed the initial extract list for concepts that mapped
into categories of patient experience that we found repre-
sented in the organ transplant PRO literature. These con-
cepts worked as tags within the text analysis program to
allow sorting and processing of the forum posts for further
review.
3 Results
3.1 Participants and Demographics
A total of 3,057 patient accounts were created in the
PatientsLikeMe Organ Transplants community between
1 March 2010 and 31 December 2010. Excluding patients
who did not report information about a specific transplant
and those reporting on multiple transplants, data from
1,924 single-organ transplant patients were included in the
analysis (Fig. 1). Patient-reported date of transplant ranged
from 10 December 1969 to 12 December 2010, with the
median number of days transplanted prior to joining
PatientsLikeMe ranging from 668 for pancreas recipients
to 1,467 for kidney recipients.
Due to the tight controls and allocation mechanisms
around organ donation, UNOS provides near-perfect data
on 28,662 organ transplants performed in the USA in 2010.
Table 1 provides a comparison of demographics between
the PatientsLikeMe organ transplant 2010 incident cohort
(patients reporting a transplant date between 1 January and
31 December 2010, n = 187) and the larger population of
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transplants performed in the USA in 2010 from UNOS
(n = 28,662).
We found significant differences between UNOS and
PatientsLikeMe users for age (v2 = 81.839, p \ 0.001),
gender (v2 = 38.191, p \ 0.001), and ethnicity
(v2 = 49.637, p \ 0.001). PatientsLikeMe users were less
likely to be children (1 % PatientsLikeMe vs. 6 % UNOS)
or seniors (2 % PatientsLikeMe vs. 15 % UNOS), with
most members being in early to middle adulthood. A
higher proportion of PatientsLikeMe users were female
(59 %) than in UNOS data (38 %), reflecting a female bias
that has been detected in other conditions such as epilepsy
or multiple sclerosis [13, 14]. PatientsLikeMe users were
more likely to be white (PatientsLikeMe 73 % vs. UNOS
60 %) with lower proportions of black (PatientsLikeMe
6 % vs. UNOS 21 %) and Hispanic (PatientsLikeMe 7 %
vs. UNOS 13 %) members but a higher proportion of users
reporting ‘‘other’’ or ‘‘mixed race’’ (PatientsLikeMe 14 %
vs. UNOS 6 %).
In addition to those receiving a transplant in 2010,
Table 2 provides additional detailed demographics of the
total PatientsLikeMe single-organ transplant population,
who might have received a transplant at any time in the
past, by organ type. The average age of patients was sig-
nificantly different across organs (F4,1690 = 5.23,
p \ 0.001) with kidney transplant patients the youngest
[42.7 years, standard deviation (SD) 12.1] and lung trans-
plant patients the oldest (46.6 years, SD 13.5). There were
also between-group differences for gender (v28 = 47.16,
p \ 0.001), with a higher proportion of female lung
recipients (60 %) relative to kidney (55 %), pancreas
(53 %), liver (49 %), or heart (38 %). Comparisons with
UNOS data were made difficult by a relatively high rate of
missing data for gender in the PatientsLikeMe sample,
around 10 % of participants. By contrast, UNOS has only
ever had a handful of transplants without gender being
recorded. Comparison of adjusted gender ratios from
PatientsLikeMe (disregarding the missing data) with 2010
data from UNOS continues to suggest a much higher
proportion of females using the site. For example, 39 % of
UNOS kidney recipients were female compared with 63 %
(adjusted) of the PatientsLikeMe sample. There were more
women than men in every organ group except heart
transplants. Most patients resided in the USA, were non-
Hispanic, and white. Given that PatientsLikeMe is cur-
rently only in English and patient recruitment efforts are
currently focused in the USA, this is not that surprising.
The majority of patients reported at least some college
education, and their health insurance is most likely to be
private, employer-based, or Medicare.
Online communities and interventions are known to
suffer from different forms of attrition, i.e., non-usage over
time [15]. Within the sample reported here, patients logged
3,057 patient accounts created 
between March 1, 2010 and 
December 31, 2010
1,924 patients included in 
analysis:
• 1,097 (57%) kidney
• 345 (18%) liver
• 288 (15%) heart
• 179 (9%) lung
• 15 (1%) pancreas
773 (25%) patients 
excluded for providing no 
information about a 
specific organ transplant
360 (12%) patients 
excluded for reporting 
multiple organ 
transplants
Fig. 1 Patient eligibility
Table 1 Demographics of United Network for Organ Sharing and









2010, n = 187)
Significance
Age (years)a
\18 1,827 (6 %) 3 (1 %) v2 = 81.839,
p \ 0.00118–34 3,225 (11 %) 50 (27 %)
35–49 6,898 (24 %) 65 (35 %)
50–64 12,420 (43 %) 61 (33 %)
65? 4,292 (15 %) 4 (2 %)
Genderb
Male 17,878 (62 %) 74 (40 %) v2 = 38.191,
p \ 0.001Female 10,784 (38 %) 110 (60 %)
Ethnicityc
White 17,161 (60 %) 137 (73 %) v2 = 49.637,
p \ 0.001Black 5,962 (21 %) 11 (6 %)
Hispanic 3,796 (13 %) 13 (7%)
Other 1,743 (6 %) 26 (14 %)
Data are given as n (%)
PLM PatientsLikeMe, UNOS United Network for Organ Sharing
a Four cases excluded from PLM dataset due to missing age data
b Three cases excluded from PLM due to missing gender data
c ‘‘Other’’ in UNOS includes: Asian, American Indian/Alaska native,
Pacific Islander, multiracial, unknown. PLM race/ethnicity categories
include: non-Hispanic white (categorized as White), non-Hispanic
black (Black), Hispanic (Hispanic), other/unknown (Other)
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in a mean of ten times in their first 365 days on the site (SD
22, median 5) and there were no significant differences in
login frequency between organ types (F4,1919 = 0.701,
p = 0.591). The distribution was highly skewed [7.325,
standard error (SE) 0.056] with a high degree of kurtosis
(68.847, SE 0.112); 80 % of users logged in ten times or
less in their first year on the site.
3.2 Quantitative Patient-Reported Outcomes
Within 30 days of account creation, 1,924 single-organ
transplant patients completed 915 symptom reports (see
Table 3). In addition to the prompted primary and sup-
plemental symptoms, patients added an additional 121




















Mean (SD) 42.7 (12.1) 45.7 (14.2) 43.8 (15.8) 46.6 (13.5) 44.3 (6.5) F4,1,690 = 5.23
p \ 0.001
Gender (%)
Female 55 49 38 60 53 v28 = 47.16
p \ 0.001Male 33 41 50 32 13
Not reported 12 10 12 8 34
Country (%)
USA 76 79 81 82 67 v28 = 12.67
p = 0.124Other country 13 11 8 11 7
Not reported 11 10 11 8 27
Ethnicity (%)
Hispanic 5 4 4 1 7 v28 = 19.89
p = 0.011Not Hispanic 66 71 72 77 40
Not reported 29 25 24 22 53
Race (%)
White 72 76 76 81 67 v212 = 26.42
p = 0.009Black 7 3 4 4 0
Other 5 6 4 2 0
Not reported 16 15 16 13 33
Education (%)
8th grade or less 1 1 1 1 0 v28 = 23.66
p = 0.481Some high school 3 2 1 3 7
High school
graduate or GED
13 13 16 17 0
Some college 35 39 37 37 47
College graduate 23 20 19 21 13
Postgraduate
degree
9 9 9 7 0
Not reported 16 16 17 14 33
Health insurance (%)
Employer-based 37 37 29 31 40 v236 = 89.81
p \ 0.001Direct purchase 2 7 3 4 0
Medicare 15 10 18 23 7
Medicaid 5 6 9 8 7
VA/military 2 2 5 1 0
Other 1 3 2 2 0
Ex-US national
insurance
5 4 5 3 7
No insurance 4 2 2 0 0
Not reported 29 29 27 28 39
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five or more patients include anemia, high blood pressure,
headache, dizziness, asthenia, tachycardia, leg cramps,
cold sensations, hyperglycemia, corticosteroid-induced
diabetes mellitus, migraine, non-Hodgkin lymphoma,
candidiasis, night cramps in legs and feet, and hand
tremors.
Symptom reports at the account creation baseline were
provided by approximately 50 % of patients. Examining
the five primary symptoms common to all organ types,
significant differences were observed for depressed mood,
anxious mood, and fatigue, with pancreas and liver patients
most likely to report their symptoms as moderate or severe.
For example, there were significant differences in depres-
sed mood by organ type (v24 = 13.89, p = 0.008), with
pancreas patients reporting a much higher rate (63 %) than
other organ types (15–21 %), although the relatively low
sample in this group (n = 8) warrants caution. Moderate or
severe insomnia was reported by at least one in three
patients in each organ group, while moderate or severe pain
was reported by at least one in six patients in each organ
group; no significant differences between organ groups
were observed.












Number of patients reporting within 30 days of
account creation, n
511 188 128 80 8
All organsa
Insomnia 33 % 37 % 39 % 41 % 65 % v24 = 8.70
p = 0.069
Depressed mood 15 % 21 % 17 % 16 % 63 % v24 = 13.89
p = 0.008
Pain 16 % 21 % 16 % 28 % 25 % v24 = 7.60
p = 0.107
Fatigue 36 % 46 % 30 % 37 % 65 % v24 = 14.37
p = 0.006
Anxious mood 18 % 22 % 23 % 31 % 63 % v24 = 17.39
p = 0.002
Organ specificb
Nausea or vomiting 6 %
Loss of appetite 8 %
Fluid retention 14 %





Shortness of breath 9 %
Problems concentrating 17 %
Persistent cough or wheeze 8 %





Rapid breathing 18 %
Abdominal pain 0 %
Indigestion 25 %
a All patients report on these five primary symptoms when filling out a symptom report (symptoms are categorized as none, mild, moderate, or
severe)
b Organ-specific symptoms included in symptom reports are based on literature review and clinician input
c ‘‘Itching’’ was added to the kidney transplant symptom report on 26 July 2010
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Users also created a total of 938 unique instances of
treatments taken within 30 days of account creation
(Table 4). When patients report a treatment they are asked
to indicate the start date (if known), purpose (e.g., ‘‘Prevent
organ rejection’’), dosage (where appropriate and pre-
populated from a list of likely dosages from the MultumTM
database), and stop date (where applicable). In addition,
patients may choose to write an ‘evaluation’ of a treatment,
resembling a consumer product review of their perceived
efficacy, side effects, burden, advice for other patients, and
reasons for discontinuation (if applicable). The average
transplant patient reported taking two treatments for the
purpose of preventing organ rejection; in addition, 25
patients voluntarily reported side effects associated with
their treatments. Forty percent or more of patients did not
enter treatment information within 30 days of account
creation.
Finally, 1,215 quality-of-life (PLMQOL) assessments
were completed. Data from 680 PLMQOL assessments
completed post 11 May 2010 demonstrate strong reliability
in each domain across organ types (Cronbach’s alpha
0.84–0.91; Table 5). Comparison shows poorer physical
scores for lung transplants than other organ groups. Com-
parison with new entrants in other PatientsLikeMe com-
munities during the same time finds average quality-of-life
scores most similar to those of HIV patients, and both
groups generally faring better than patients with epilepsy,
fibromyalgia and ME, mood disorders, Parkinson’s disease,
multiple sclerosis, or ALS (see Fig. 2; Table 6). The rela-
tively better scores of organ transplant and HIV patients











% of patients reporting any treatments spanning
baseline account creation date (n)
47 % (513) 56 % (193) 47 % (135) 51 % (91) 40 % (6)
Median number of immunosuppressants patients
report currently taking (range)
2 (0–5) 1 (0–4) 2 (0–5) 2 (0–4) 2 (0–3)
Median number of treatments patients report currently taking (range) 3 (1–24) 2 (1–14) 2 (1–24) 4 (1–33) 2 (1–5)
Number of patients reporting treatment side effects
during period from account creation to end of observation period
12 6 4 3 0
Table 5 Quality of life basic
psychometric properties
Reliability is defined by
Cronbach’s alpha
SD standard deviation
a Number of patients reporting
quality of life after 11 May
2010, when the most recent













na 386 131 91 65 7
Physical score (0–4)
Mean 37 36 36 33 36 F4,675 = 5.54
p \ 0.001SD 7.1 7.1 8 10 9.7
% floor 0 0 0 0 0
% ceiling 21 17 17 9 29
Reliability 0.91 0.91 0.92 0.93 0.93
Mental score (0–32)
Mean 24 24 25 23 21 F4,675 = 0.60
p = 0.664SD 6.7 6.4 7.3 7.5 9.9
% floor 0 0 1 0 0
% ceiling 10 12 19 14 14
Reliability 0.92 0.91 0.93 0.91 0.93
Social score (0–20)
Mean 15 15 15 13 12 F4,675 = 2.32
p = 0.056SD 4.5 4.5 4.9 5.7 6.4
% floor 1 1 2 3 0
% ceiling 22 19 22 14 29
Reliability 0.84 0.85 0.86 0.91 0.91
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using PatientsLikeMe in comparison with the other disease
groups may suggest such patients are benefitting from
relatively effective long-term treatment regimens.
3.3 Qualitative Review of Forum and Treatment
Evaluations
Between March and December 2010, there were 2,169 posts
to 346 unique topic threads in the transplants forum. This
content was contributed by 605 unique users (patients,
caregivers, guests, and site administrators), 304 of whom
made only one post. These one-off posts fell into the fol-
lowing categories: Introductory posts (e.g., ‘‘Hi I’m new
here…’’), questions (e.g., ‘‘Has anyone else had a gastric
bypass?’’), reply posts expressing similar experiences (e.g.,
‘‘Susan, I’ve had that too…’’), or posts offering information
(e.g., ‘‘Try setting an alarm on your phone to remember
meds’’). These one-off posts were not qualitatively different
from those made from members posting multiple times.
In total, 208 different users initiated the 346 forum
threads, although a core of 47 users creating two or more
threads accounted for 186 (54 %) of the threads. A total of
636 posts were not automatically classified; upon further
review, 32 were forced into existing categories. A total of
1,565 posts were subject to further review. A single tag was
applied to 692 of the posts, two tags were applied to 407 of
the posts, and three or more tags were applied to the
remaining 466 posts (Table 7). The most common tags
included ‘‘organs,’’ ‘‘symptoms,’’ and ‘‘side effects’’, fol-
lowed by ‘‘exercise and activity,’’ ‘‘satisfaction,’’ and
‘‘fear.’’ Open-text analysis of 304 treatment evaluation
entries reveals common tags of ‘‘symptoms,’’ ‘‘side
effects,’’ and ‘‘compliance,’’ closely mirroring results of
the forum analysis (Table 8).
Fig. 2 Quality of life of
patients reporting within
30 days of PatientsLikeMe
account creation. All single-
organ transplants are compared
with new entrants to existing
PatientsLikeMe communities
(higher scores represent better
quality of life). Data from
quality-of-life reports obtained
between 11 May 2010 and 31
December 2011. ALS
amyotrophic lateral sclerosis
Table 6 Quality of life comparison of organ transplant with other
PatientsLikeMe communities
Physical score Mental score Social score
ALS (n = 81)
Mean 23 21 13
SD 12.0 6.8 4.6
Multiple sclerosis (n = 126)
Mean 30 20 12
SD 9.7 7.7 5.3
Parkinson’s disease (n = 65)
Mean 29 21 13
SD 10.8 6.3 5.1
Mood disorders (n = 235)
Mean 35 16 11
SD 8.1 7.7 4.8
HIV (n = 85)
Mean 38 21 13
SD 7.6 7.4 5.0
Fibromyalgia and ME (n = 219)
Mean 23 16 8
SD 8.9 6.5 4.6
Epilepsy (n = 104)
Mean 34 20 13
SD 8.5 8.1 5.1
All single-organ transplants (n = 680)
Mean 36 24 15









Data from quality-of-life reports obtained between 11 May 2010 and
31 December 2011
ALS amyotrophic lateral sclerosis, ME myalgic encephalomyelitis, SD
standard deviation
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4 Discussion
The organ transplant community on PatientsLikeMe pro-
vides tools to help patients share post-transplant experience
among their peers. Within 9 months of launch, nearly
2,000 single-organ patients registered to use the system,
and half of these provided data relating to their organ,
quality of life, treatments, or symptoms. The use of
structured and transplant-specific questions allowed com-
parison of the self-reported data to an established data
source, UNOS/OPTN, while open-text narrative data
allowed members to spontaneously report their concerns in
their own patient voice.
Between March and December 2010, nearly 1 % of all
patients receiving an organ transplant in the USA joined
PatientsLikeMe. That is not to say that this group was
wholly representative, however, with users tending to be
adults rather than children or seniors, with a higher pro-
portion of females and whites than national data. The rel-
atively low rate of use by children and seniors has been
observed previously when comparing PatientsLikeMe
epilepsy users against insurance claims data [13]. It is
likely that the site’s focus on technically literate adult
patients may be off-putting to parents of unwell children,
who feel the site does not yet address their needs. Internal
research is underway to better understand the needs of this
group to help them find ‘‘ParentsLikeMe’’. Seniors might
feel excluded by the requirement for Internet access and a
relatively modern web browser, a digital divide that is
likely to close over time. The different pattern of racial
groups accessing the site might reflect different preferences
for information seeking, marketing channels used to recruit
patients, and, in the case of the relatively low proportion of
Hispanic patients, the lack of availability of any language
than English in the current version of the site. While some
online communities such as TuDiabetes (http://www.
tudiabetes.org) benefit from a Spanish-language version
(EsTuDiabetes; http://www.estudiabetes.org), important
issues such as adverse event reporting, safe and accurate
communication between members, community moderation,
and management of symptom terminology raise logistical
barriers to multi-lingual sites.
While outcomes such as survival, rejection, hospital-
ization, and adverse events are collected routinely, less data
have been collected with regard to quality-of-life out-
comes. The reported experience of users of Patients-
LikeMe, as in conventional quality-of-life assessment for
transplant patients, reveals experience of symptoms that





























a Multiple tags may be applied to any entry
Table 8 Frequency of tag application to 304 categorized advice




















a Multiple tags may be applied to any entry
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may relate to the functioning of the transplanted organ. For
example, the following symptoms were reported as mod-
erate or severe by 15 % or more of patients at the time they
joined the site: fluid retention in kidney patients, drowsi-
ness in liver patients, palpitations in heart patients, various
chest problems in lung patients, or indigestion in pancreas
patients. We are also obtaining reports of symptoms asso-
ciated with treatment, such as dizziness or hand tremors,
but with low frequency as indicated by added symptoms
and treatment adverse effect reports. The system includes
features that permit spontaneously reported experiences to
be quickly added to standard question items, ensuring the
community continuously learns. There is even the potential
for these data to be fed back into common ontologies to
better inform the wider field [16].
Responses to the PLMQOL questions show that, on
average, at baseline, users of the site were doing relatively
well. Average scores in each of the three major domains—
physical, mental, and social—were toward the upper (good
quality) end of the possible range, although as demon-
strated by the ceiling estimates only 10–20 % (depending
on organ type or domain) were responding that they were
free of limitations due to their health. The data shown here
indicate organ recipients as a group are doing better in each
domain than patients with other significant life-altering
conditions (Fig. 2).
PROs are gaining increasing prominence as useful tools
in the measurement of medicine, for instance in detecting
important outcomes such as fatigue in cancer [17], the
detection of adverse events for marketed drugs [18], risk
management programs for drugs with a high risk profile
[19], and non-primary endpoints in the labels of newly
approved drugs [20]. However, methodological limitations
of PROs remain, such as unblinding, dealing with missing
data, and cross-cultural validation of instruments. Online
systems represent one method for experimentally address-
ing these limitations faster than traditional methods to
boost the reliability and credibility of PROs with a view to
exploring new uses they might one day have such as
comparative effectiveness research.
In our experience, PRO research conducted online
works best when a known, targeted group can be invited to
participate in a study that directly addresses questions they
are interested in, using brief cross-sectional surveys (less
than 100 items is recommended), and with participants
receiving immediate feedback on the data they contribute
(such as where they lie in a distribution) in order to convey
to them the value of participating in research. Response
rates can be boosted with direct incentives (e.g., gift cards)
or indirect incentives (e.g., donation to a non-profit) but are
unlikely to rise to the response rate of questionnaires
administered during a clinical visit. Longitudinal studies
are difficult to maintain as it is easy for participants to
ignore requests to participate, particularly when they come
at arbitrary time points such as ‘‘three months later’’, rather
than a meaningful trigger to the patient such as a change in
their clinical status.
Much discussion exists around the advantages, disad-
vantages, and application of the Internet in the context of
research [21, 22]. Key factors include condition, research
question, and engagement. The most successful commu-
nities on our platform are for patients with conditions that
are relatively rare, serious, with sufferers likely to be
female and below the age of 60 years, and where the
patient’s actions and behaviors are likely to influence the
outcome of their condition. Research questions that tap into
the types of issues that patients spontaneously discuss with
one another and complain about are more likely to yield
greater response rates than questions of either purely aca-
demic or commercial interest. Online tools may be par-
ticularly useful in gaining rapid feedback where patient
input is key, such as in the development of new PROs,
where guidance from the FDA suggests this is a necessary
component of scale validation [23]. PatientsLikeMe has
recently announced the development of an ‘‘Open Research
Exchange,’’ which will allow PRO developers to prototype
and test new PROs with users of the system willing to
provide feedback and complete PROs in test phases to
develop better instruments.
In moving from the conduct of research by human data
collection to online studies there is an important consid-
eration of engagement, an online form of rapport. In a
traditional ‘offline’ clinical study, although there are
(somewhat dry) informed consent documents to read
through, a participant might also get the opportunity to
meet an enthusiastic young researcher and have the ability
to ask them other questions in order to learn more about
their condition. In an online setting, however, this warmth,
human interaction, and opportunity for serendipitous dis-
covery is missing. In the online world these may be
addressed in a different way, through design, but it is
unclear the extent to which these will be important in
maximizing response rates and value.
PatientsLikeMe aims to blend the power and ‘stickiness’
of social media and social networking with the rigors of
structured observational data collection and analysis. In the
context of organ transplantation, the Internet has histori-
cally been used as a mechanism to match donor organs
with recipients. In addition, several websites exist that host
forum capabilities and provide links to various transplant-
related resources. More broadly, websites and smartphone
applications exist for patients with many health conditions,
including organ transplant, to help individuals monitor
their own health and medication information. Patients-
LikeMe actively encourages capturing and sharing com-
plex real-world information that is relevant to organ
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transplant, but also information that is relevant to under-
standing the patient context and experience.
This study may have implications for other conditions
that involve surgical follow-up, such as prompting patients
during the discharge period that they will receive an
electronic follow-up at a relevant time point in the future
and that, in the meantime, in addition to the support of their
healthcare team, they will have access to the health expe-
riences of other patients who have recovered from the same
surgery. Because only a subset will be engaged longitudi-
nally, it would be important to capture the most important
PRO data in the first session visit in case the patient does
not return. Future research will consider whether longitu-
dinal attrition can be improved by integrating online data
entry to a clinical visit.
This study had a number of limitations. Compared with
the population-level data collected by UNOS, users of our
system were found to be younger, more likely to be female,
and more likely to be white. This may be reflective of the
self-selecting nature of patients who come to the website
and may affect the ability to generalize our findings.
Inherent in any type of observational research is the
potential for selection bias, information bias, and con-
founding, and such limitations may be amplified in
research conducted via the Internet. Additionally, patients
in our system can report retrospectively, which may be
particularly prone to bias, hence our use of 2010 incident
transplants in our comparative analysis. Some data, such as
lab tests and dates of transplant and hospitalizations, may
be accessible to patients in written or electronic records.
However, retrospective PROs such as quality of life,
symptom severity, or treatment evaluations may be less
reliable. Unlike UNOS, we have no independent validation
that patients are who they say or that they have truly
received an organ transplant. However, the platform is
policed by full-time moderators to look for signs of
advertising or illegal services (such as attempting to ‘sell’
an organ), and technical measures are used to identify
automated programs or attempts to register multiple
accounts from the same source. A number of tools are also
in place for users of the system to report suspicious activity
to these moderators. There is currently little incentive for
anyone to systematically enter falsified data, though this is
a risk. Future research is underway to address means of
independent validation that preserve some desirable ele-
ments of the platform, such as anonymity.
Finally, it is worth noting that organ transplantation has a
unique resource in UNOS. In no other condition in the USA
can the public access almost 100 % complete, accurate, and
up-to-date data on a medical condition. If such compre-
hensive data were available for every medical condition
there would be no need for patients and researchers to
develop innovative new methods to learn about one another.
5 Conclusion
Our initial description of this online community suggests
significant opportunity in the space of PROs, symptoms, and
side effects. However, there are also limitations of limited
size, bias in the sample, attrition, and the nature of data that
can be reported online. Integration of online communities
into the transplant process could overcome some of these
limitations and perhaps even yield other benefits.
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